Singapore markets closed
Straits Times Index
3,215.40 +10.58 (+0.33%) S&P 500
4,320.06 -9.94 (-0.23%) Dow
33,963.84 -106.56 (-0.31%) Nasdaq
13,211.81 -12.19 (-0.09%) Bitcoin USD
26,088.97 -495.62 (-1.86%) CMC Crypto 200
557.90 -10.15 (-1.79%)
Atea Pharmaceuticals, Inc. (AVIR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 3.1800 |
| Open | 3.2000 |
| Bid | 3.1800 x 1000 |
| Ask | 3.2700 x 1400 |
| Day's range | 3.1800 - 3.2400 |
| 52-week range | 2.9400 - 6.3200 |
| Volume | |
| Avg. volume | 348,204 |
| Market cap | 266.878M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2800 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
ZacksAtea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksAfter Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksWhy Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
© 2023 Yahoo. All rights reserved.
